Active, not recruitingPhase 2NCT06100913
Immunology of Ebola Vaccine
Studying Ebola hemorrhagic fever
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Emory University
- Principal Investigator
- Nadine Rouphael, MDEmory University
- Intervention
- Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP)(biological)
- Enrollment
- 30 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2027
Study locations (2)
- The Hope Clinic of the Emory Vaccine Center, Decatur, Georgia, United States
- Washington University in St. Louis, St Louis, Missouri, United States
Collaborators
Washington University School of Medicine · Merck Sharp & Dohme LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06100913 on ClinicalTrials.govOther trials for Ebola hemorrhagic fever
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT05992480REVIVE (Response to the Ebola Virus Vaccine)Tulane University
- ACTIVE NOT RECRUITINGPHASE2NCT06803342A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy AdultsAlbert B. Sabin Vaccine Institute
- RECRUITINGPHASE3NCT06126822Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination with the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRCInstitute of Tropical Medicine, Belgium